Head of Rheumatology and Translational Research
Institute of Infection and Immunity
Director of Arthritis Research UK CREATE Centre and
Welsh Arthritis Research Network (WARN) Cardiff University School of Medicine
Cardiff, United Kingdom
Related Videos
Video
What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?
Video
How does the IL-6 pathway and family of cytokines affect inflammation and non-joint clinical manifestations?
Video
What biomarkers, clinical findings, or previous treatment history do you rely on to identify patients who might be uniquely responsive to IL-6 inhibition?
Video
Can you discuss the unique mechanistic effects of IL-6 inhibition — including the role of GP 130 — that differentiate it from other cytokines that are targeted in RA? Can its signaling properties be transmitted to sites distal from inflammation?
Video
Is there a systematic approach for aligning specific cohorts of patients with RA with specific therapies? With IL-6 inhibitors, TNFIs, or co-modulating activating agents?
Video
What disease activity measures for RA do you consider to be most important?
What disease activity measures for RA do you consider to be most important?
Video
Can you compare the translational implications of inhibiting the TNF vs IL-6 cytokine signaling systems? How are these differences manifested clinically?
Video
When are combination approaches — with a DMARD and biologic — used to treat RA and when might monotherapeutic approaches be preferable?
